World of DTC Marketing

AUGUST 3, 2022

At first, the opportunity to join a small biotech startup sounds excellent. Smaller staff usually means less bureaucracy and being on the ground floor of a potentially financially rewarding career. But there are risks. Leaving the comforts of a big company with a calcified infrastructure, laser-focused job roles, well-established SOPs, deeper pockets, and excellent job security for the scramble and chaos of a younger company isn’t for everyone. .

Pharma 242

Pharma Physicians Marketing Patients 242

pharmaphorum

AUGUST 3, 2022

We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and improve patient outcomes – so what’s holding us back? It’s been more than two decades since the ground-breaking potential of using electronic health records (EHR) to inform clinical research was first mooted. Since then, progress has been slow, but the industry now has everything it needs to close the feedback loop between science, evidence, and care, said speakers at a recent Co

Electronics 109

Electronics Healthcare Healthcare Patients 109

MedCity News

AUGUST 3, 2022

Though the wage increase is a win for some, questions remain about where the money will come from and hospitals are concerned pay disparities will impact vulnerable communities most.

Healthcare 109

Healthcare Healthcare 109

Salesforce

AUGUST 3, 2022

If you’re worried about the ever-changing nature of work and what the future holds for your company, you’re not alone. The long-established social contract between employees and employers is being rewritten on a global scale. One thing is clear – there is not a singular future of work. There will be a variety of futures available to your organization, and you will need to decide which one makes sense, and how to create it.

Retail 98

Retail Management Sales Consulting 98

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

MedCity News

AUGUST 3, 2022

With the recent disclosure of its Q2 financial results, Teladoc’s losses have swelled to nearly $10 billion in the first half of 2022. Ali Parsa, CEO of competitor Babylon Health, said Teladoc can look at what Amazon did 20 years ago as an example of how to navigate an unforgiving economic environment, recommending the company reorganize its expenditures to ensure capital is allocated to areas that will differentiate it from its competitors.

109

109

Storyvine

AUGUST 3, 2022

Close the “Relationship Gap” with Personalized Video. By far, the best way to develop relationships is face-to-face, and sales people have relied on “pressing the flesh” for years, even after the advent of Customer Relationship Management technology and tools. Human interaction is key, especially when you have a complicated sales process, but how do you establish & grow relationships in a world where in-person meetings are dramatically reduced, if not canceled altogether—where your most powe

Customer Relationship Management 98

Customer Relationship Management Sales Relationship management Pharma 98

Medgadget

AUGUST 3, 2022

Scientists at the Royal College of Surgeons in Ireland and partners at the National College of Art and Design in Dublin have developed a silicone heart model that is intended to model heart failure with preserved ejection fraction. The device, which represents a ‘mock circulatory loop’, includes a simulated version of the left atrium and left ventricle, and each chamber is independently controlled to model the entire cardiac cycle.

Medicine 96

Medicine Patients Medical 96

MedCity News

AUGUST 3, 2022

Billions—to trillions—of dollars are wasted in healthcare spend and although progress has been made toward closing the gap, opportunity remains in often overlooked places. Redundant care is frequently the cost culprit that is being overlooked.

Healthcare 104

Healthcare Healthcare 104

European Pharmaceutical Review

AUGUST 3, 2022

Ph. Eur. The European Pharmacopoeia (Ph. Eur.) Commission has established the mRNAVAC Working Party to begin working on quality standards to support the emerging field of messenger RNA (mRNA) vaccines. The newly created Working Party’s first task will be to develop a consolidated strategy for future standards addressing these vaccines and their components.

Manufacturing 94

Manufacturing Government Safety Medicine 94

MedCity News

AUGUST 3, 2022

In a world where care delivery and patient-to-provider interactions are increasingly facilitated by digital tools, and the makers of those tools count hundreds—even thousands—of healthcare organizations as customers, technology should be a central part of the healthequity discussion.

Healthcare 104

Healthcare Healthcare Patients 104

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

AUGUST 3, 2022

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter. Cell therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) for lymphoma and leukaemia together brought in $368 million, up 68%, while antibody drug conjugate Trodelvy (sacituzumab govitecan) rose 79% to $159 million thanks to increased uptake in triple-negative breast canc

Sales 93

Sales Management Marketing 93

MedCity News

AUGUST 3, 2022

UCLA Health recently announced the inaugural cohort of startups for its health equity accelerator. The seven digital health startups, which represent pre-seed through Series A-stage companies, are developing digital health solutions to address chronic disease management, respiratory illness and healthcare accessibility for vulnerable populations.

Healthcare 104

Healthcare Healthcare Management 104

pharmaphorum

AUGUST 3, 2022

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases. The agreement with Poseida is by far the larger of the two, with Roche paying $110 million upfront to license rights to off-the-shelf CAR-T therapies aimed at haematological cancers, including one targeting BCMA on phase 1 testing and another targeting CD19 and CD20 that is due to start trials in 2023 – known as the tier 1 candidates.

Pharmaceutical 84

Pharmaceutical 84

MedCity News

AUGUST 3, 2022

A panel discussion from a recent Microsoft summit offered insights on how tech companies are closely collaborating with the pharma industry as they seek to repair and improve manufacturing supply chain issues exposed by the Covid-19 pandemic.

Pharma 98

Pharma Manufacturing Biopharma 98

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

PharmaVoice

AUGUST 3, 2022

How these latest executive personnel changes are impacting the industry.

105

105

MedCity News

AUGUST 3, 2022

About 5.2 million people have gained healthcare coverage since 2020. The previous record for the lowest national uninsured rate was 9% in 2016. .

Healthcare 109

Healthcare Healthcare 109

PharmaTimes

AUGUST 3, 2022

The sites will maximise local and global benefits of NHS, research, industry and community partnerships

87

87

MedCity News

AUGUST 3, 2022

Instead of offering employees multiple different point solutions, employers can work with UCM Digital Health to create a package that integrates all the solutions in one place. Patients can access UCM by app, computer or phone.

Patients 97

Patients 97

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PharmaTimes

AUGUST 3, 2022

Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies

87

87

pharmaphorum

AUGUST 3, 2022

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in the class. The five-year-old Chinese company – which is developing drugs for age-related degenerative diseases – said it will use the proceeds of the Series B to support the clinical development of its RIPK1 inhibitors as well as to expand its pipeline of drug candidates in other classes.

Leads 59

Leads Pharmaceutical Patients 59

Pharmaceutical Technology

AUGUST 3, 2022

Rigel Pharmaceuticals has signed a licence agreement with Forma Therapeutics for developing, producing and marketing olutasidenib to potentially treat relapsed/refractory acute myeloid leukaemia (R/R AML) and other types of cancer. . Olutasidenib, an investigational agent, is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) that attaches to and hinders mutated IDH1 enzymes.

Food and Drug Administration 59

Food and Drug Administration Food Marketing Pharmaceutical 59

Pharmatutor

AUGUST 3, 2022

HERBAL / NATURAL INGREDIENTS FOR SKIN NOURISHMENT FROM A TO Z. About Authors. Avdesh Thassu. MPharm (Nat. Chem.); MBA(Mkt.). admin. Wed, 08/03/2022 - 15:44. Tags. Articles.

59

59

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management

pharmaphorum

AUGUST 3, 2022

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC). In the RESILIENT study, Onivyde – a liposomal formulation of the well-established cytotoxic drug irinotecan – was unable to improve overall survival when used as a monotherapy after first-line platinum chemotherapy for SCLC, when compared to generic therapy topotecan.

Prospecting 52

Prospecting FDA Sales Patients 52

Pharmaceutical Technology

AUGUST 3, 2022

Gilead Sciences has reported a 1% growth in revenue to $6.3bn in the second quarter (Q2) of 2022 as against $6.2bn in the year-ago quarter. The company attributed the revenue rise to enhanced sales in HIV and oncology products, which was offset partially by reduced sales of Veklury (remdesivir) and hepatitis C virus (HCV) medicines. For the three months ended on 30 June 2022, diluted earnings per share (EPS) declined to $0.91 from $1.21 in Q2 2021.

Sales 52

Sales Medicine Pharmaceutical 52

Spotio

AUGUST 3, 2022

ADDISON, TX – SPOTIO announces the opening of their new headquarters located at 5057 Keller Springs Road in Addison, TX to accommodate the rapid growth that the business has experienced in recent years. SPOTIO is a Dallas-based SaaS platform that enables field sales teams to become more efficient and productive since they began operations in 2014. “Since the beginning, SPOTIO’s focus has been to help field sales achieve more and we’ve been fortunate enough to be successful in t

Sales 52

Sales 52

Pharmaceutical Technology

AUGUST 3, 2022

The proportion of pharmaceutical companies hiring for internet of things related positions rose in July 2022 compared with the equivalent month last year, with 18.2% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 14.6% of companies who were hiring for internet of things related jobs a year ago but a decrease compared to the figure of 19.7% in June 2022.

Pharmaceutical 52

Pharmaceutical Recruitment 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmacy Times

AUGUST 3, 2022

Findings in a new trial show that dietary supplementation of resistant starch has the potential to decrease people’s risk of certain types of gastrointestinal cancers.

Food 59

Food 59

Copyright Clearance Center

AUGUST 3, 2022

The post CCC Expands Corporate Solutions Offering with New Technology appeared first on Copyright Clearance Center.

52

52

PharmExec

AUGUST 3, 2022

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Patients 59

Patients 59

PharmaVoice

AUGUST 3, 2022

The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

52

52

Advertisement

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.

Patients